Bionomics Analyst Ratings
H.C. Wainwright Maintains Bionomics(BNOX.US) With Buy Rating, Maintains Target Price $8
Bionomics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Bionomics, Maintains $8 Price Target
Buy Rating Affirmed on Bionomics as BNC210 Enters Critical Phase 3 Trial for Social Anxiety Disorder
Bionomics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Bionomics, Maintains $8 Price Target
Buy Rating Affirmed for Bionomics' BNC210 Following Promising PTSD Study Results
Bionomics's BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis
Bionomics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Bionomics, Maintains $8 Price Target
Bionomics Analyst Ratings
Promising Progress of BNC210 Bolsters Buy Rating on Bionomics Amidst Rising Interest in SAD Treatments
Positive Phase 2b Study Results Bolster Buy Rating for Bionomics' PTSD Drug BNC210
Maxim Group Maintains Buy on Bionomics, Raises Price Target to $10
HC Wainwright & Co. Upgrades Bionomics to Buy, Announces $8 Price Target
Bionomics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (TVTX) and Bionomics (BNOX)
Maxim Group Initiates Coverage On Bionomics With Buy Rating, Announces Price Target of $7
H.C. Wainwright Keeps Their Hold Rating on Bionomics (BNOX)
No Data